Menu Search
Equities

Jubilant Pharmova Ltd

JUBLPHARMA:NSI

Jubilant Pharmova Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,190.30
  • Today's Change-31.70 / -2.59%
  • Shares traded338.91k
  • 1 Year change+189.51%
  • Beta1.8798
Data delayed at least 15 minutes, as of Nov 12 2024 10:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Jubilant Pharmova Ltd grew revenues 6.70% from 62.82bn to 67.03bn while net income improved from a loss of 609.80m to a gain of 771.00m.
Gross margin68.50%
Net profit margin8.51%
Operating margin12.51%
Return on assets5.05%
Return on equity10.45%
Return on investment6.01%
More ▼

Cash flow in INRView more

In 2024, cash reserves at Jubilant Pharmova Ltd fell by 575.00m. However, the company earned 9.71bn from its operations for a Cash Flow Margin of 14.49%. In addition the company used 6.08bn on investing activities and also paid 4.33bn in financing cash flows.
Cash flow per share60.96
Price/Cash flow per share20.09
Book value per share375.04
Tangible book value per share150.71
More ▼

Balance sheet in INRView more

Jubilant Pharmova Ltd has a Debt to Total Capital ratio of 34.20%, a lower figure than the previous year's 62.23%.
Current ratio1.80
Quick ratio1.20
Total debt/total equity0.5185
Total debt/total capital0.342
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 226.67%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
Div yield(5 year avg)1.17%
Div growth rate (5 year)2.13%
Payout ratio (TTM)13.42%
EPS growth(5 years)-33.33
EPS (TTM) vs
TTM 1 year ago		1,456.04
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.